BLC
CPRX

Brown, Lisle/Cummings’s Catalyst Pharmaceutical CPRX Stock Holding History

Brown, Lisle/Cummings’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.42K Buy
77
+51
+196% +$1.5K ﹤0.01% 826
2026
Q1 		$644 Buy
+26
New +$619 ﹤0.01% 970

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Brown, Lisle/Cummings's CPRX Position: Q2 2026 in Review

Brown, Lisle/Cummings increased its Catalyst Pharmaceutical (CPRX) stake by 196% in Q2 2026, buying an estimated $1.5K and bringing the position to 77 shares worth $2.42K. The position accounts for ﹤0.01% of the portfolio, ranked #826.

Brown, Lisle/Cummings first reported a position in CPRX in Q1 2026 and has held it in 2 quarters since. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Brown, Lisle/Cummings held 77 shares of Catalyst Pharmaceutical worth $2.42K as of Q2 2026.
  • Brown, Lisle/Cummings bought 51 Catalyst Pharmaceutical shares in Q2 2026, an estimated $1.5K.
  • Catalyst Pharmaceutical made up ﹤0.01% of Brown, Lisle/Cummings's portfolio in Q2 2026, its #826 holding.
  • Brown, Lisle/Cummings first reported a position in Catalyst Pharmaceutical in Q1 2026 and has held it in 2 quarters since.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Brown, Lisle/Cummings's 13F filing for Q2 2026, filed 2 Sep 2026.